Loading...
XNAS
COLL
Market cap1.16bUSD
Jul 09, Last price  
35.81USD
1D
-0.06%
1Q
0.96%
Jan 2017
129.99%
IPO
176.53%
Name

Collegium Pharmaceutical Inc

Chart & Performance

D1W1MN
XNAS:COLL chart
P/E
18.47
P/S
1.49
EPS
1.94
Div Yield, %
Shrs. gr., 5y
2.46%
Rev. gr., 5y
20.28%
Revenues
781m
+23.62%
0001,711,00028,476,000280,413,000296,701,000310,016,000276,868,000463,933,000566,767,000631,449,000780,567,000
Net income
63m
-9.13%
-16,197,000-17,917,000-27,255,000-94,176,000-74,865,000-39,128,000-22,722,00026,752,00071,517,000-25,002,00048,155,00069,190,00062,870,000
CFO
329m
+60.66%
-16,530,000-17,947,000-21,567,000-75,053,000-67,018,000169,390,00027,783,00093,942,000103,557,000124,230,000274,749,000204,980,000329,323,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
IPO date
May 07, 2015
Employees
207
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT